US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Soligenix, Inc.

1.12

-0.0100-0.88%

Post-market: 1.11-0.0100-0.89%18:14 EST

Volume:114.39K

Turnover:130.87K

Market Cap:11.30M

PE:-0.33

High:1.18

Open:1.14

Low:1.12

Close:1.13

52wk High:6.23

52wk Low:1.02

Shares:10.09M

Float Shares:7.93M

Volume Ratio:0.58

T/O Rate:1.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.3894

EPS(LYR):-4.9786

ROE:-165.10%

ROA:-69.38%

PB:1.49

PE(LYR):-0.22

Loading ...

Overview Company News Filings

BRIEF-Soligenix Inc Enters Sales Agreement With Rodman

Soligenix Showcases Rare Disease Pipeline and Market Potential in New Corporate Presentation

Soligenix Reports Positive Phase 2 Results for SGX945 in Behçet's Disease

Soligenix Inc - Sgx945 Well-Tolerated With No Treatment-Related Adverse Events

THOMSON REUTERS

Positive Clinical Results From Phase 2 Trial of Sgx945 for the Treatment of BehÇEt's Disease Published in Rheumatology (Oxford)

THOMSON REUTERS

Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302

Soligenix Reports Positive Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis

Soligenix Inc - Study Confirms Sgx302 Improves Psoriasis Lesions

THOMSON REUTERS

Soligenix Inc - Optimized Gel Formulation Shows Success in Third Cohort

THOMSON REUTERS

Soligenix Announces Top-Line Results of the Phase 2a Study of Sgx302 (Synthetic Hypericin) in Patients With Mild-to-Moderate Psoriasis

THOMSON REUTERS

Soligenix Inc - Sgx302 Gel Therapy Well Tolerated With No Adverse Events

THOMSON REUTERS

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

Soligenix Reaches Interim Enrollment Milestone in Phase 3 HyBryte Trial for CTCL

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™ for the Treatment of Cutaneous T-Cell Lymphoma

THOMSON REUTERS

Soligenix Regains Nasdaq Compliance After Equity Shortfall

Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends

Soligenix Reports Net Loss of $2.5 Million With No Revenue in Q3 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNGX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SNGX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","market":"US","secType":"STK","nameCN":"Soligenix, Inc.","latestPrice":1.12,"timestamp":1770670800000,"preClose":1.13,"halted":0,"volume":114386,"hourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.12,"latestTime":"18:14 EST","volume":1787,"amount":1987.874883,"timestamp":1770678844947,"change":-0.01,"changeRate":-0.008929,"amplitude":0.011429},"delay":0,"changeRate":-0.008849557522123706,"floatShares":7928900,"shares":10086130,"eps":-3.389437,"marketStatus":"Post-Mkt","change":-0.01,"latestTime":"02-09 19:06:33 EST","open":1.14,"high":1.1844,"low":1.12,"amount":130871.33319719999,"amplitude":0.056991,"askPrice":1.25,"askSize":500,"bidPrice":1.1,"bidSize":4400,"shortable":3,"etf":0,"ttmEps":-3.389437,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770685200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.13,"preHourTrading":{"tag":"盘前","latestPrice":1.1089,"preClose":1.13,"latestTime":"08:51 EST","volume":3307,"amount":3614.5559605,"timestamp":1770645065829,"change":-0.0211,"changeRate":-0.018673,"amplitude":0.079469},"postHourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.12,"latestTime":"18:14 EST","volume":1787,"amount":1987.874883,"timestamp":1770678844947,"change":-0.01,"changeRate":-0.008929,"amplitude":0.011429},"volumeRatio":0.579233},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","floatShares":7928900,"roa":"-69.38%","roe":"-165.10%","lyrEps":-4.978626,"volumeRatio":0.579233,"shares":10086130,"dividePrice":0,"high":1.1844,"amplitude":0.056991,"preClose":1.13,"low":1.12,"week52Low":1.02,"pbRate":"1.49","week52High":6.2299,"institutionHeld":0.088,"latestPrice":1.12,"committee":0.795918,"eps":-3.389437,"divideRate":0,"volume":114386,"delay":0,"ttmEps":-3.389437,"open":1.14,"prevYearClose":1.34,"prevWeekClose":1.13,"prevMonthClose":1.25,"prevQuarterClose":1.34,"fiveDayClose":1.23,"twentyDayClose":1.35,"sixtyDayClose":1.42},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNGX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-07","symbol":"SNGX","fiscalQuarterEnding":"2025/09","expectedEps":-0.63,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2025-08-14","symbol":"SNGX","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2025-05-09","symbol":"SNGX","fiscalQuarterEnding":"2025/03","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":-1.06},{"market":"US","date":"2025-03-21","symbol":"SNGX","fiscalQuarterEnding":"2024/12","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742529600000,"reportTimeType":"pre","actualEps":-1.14},{"market":"US","date":"2024-11-08","symbol":"SNGX","fiscalQuarterEnding":"2024/09","expectedEps":-1.09,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":-0.78}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNGX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNGX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1752814800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SNGX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SNGX","date":"2026-02-06","current":-0.330438,"percent":0.628757,"low":-4.926165,"twenty":-2.392653,"median":-1.223977,"eighty":-0.616672,"high":-0.277411,"avg":-1.535165,"sd":1.014884,"marketCap":10489575},"quantilePoints":[{"date":"2021-02-12","current":-4.485954,"twenty":-3.822137,"median":-3.02874,"eighty":-2.116451,"marketCap":67378666},{"date":"2021-02-19","current":-3.982857,"twenty":-3.833505,"median":-3.030551,"eighty":-2.116451,"marketCap":59822181},{"date":"2021-02-26","current":-3.458797,"twenty":-3.833505,"median":-3.03163,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-03-05","current":-3.207248,"twenty":-3.835264,"median":-3.031519,"eighty":-2.11619,"marketCap":48172598},{"date":"2021-03-12","current":-3.75227,"twenty":-3.835264,"median":-3.03243,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-19","current":-3.75227,"twenty":-3.83612,"median":-3.040991,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-26","current":-3.270135,"twenty":-3.835838,"median":-3.042299,"eighty":-2.116451,"marketCap":49117159},{"date":"2021-04-01","current":-3.529516,"twenty":-3.826467,"median":-3.042299,"eighty":-2.116451,"marketCap":62431916},{"date":"2021-04-09","current":-3.41639,"twenty":-3.822157,"median":-3.042299,"eighty":-2.11619,"marketCap":60430892},{"date":"2021-04-16","current":-2.963888,"twenty":-3.822157,"median":-3.041843,"eighty":-2.11619,"marketCap":52426802},{"date":"2021-04-23","current":-3.212764,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":56829052},{"date":"2021-04-30","current":-3.258014,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":57629461},{"date":"2021-05-07","current":-2.896013,"twenty":-3.808915,"median":-3.033651,"eighty":-2.11619,"marketCap":51226187},{"date":"2021-05-14","current":-2.013634,"twenty":-3.807849,"median":-3.030979,"eighty":-2.11619,"marketCap":35618208},{"date":"2021-05-21","current":-3.342664,"twenty":-3.807849,"median":-3.034785,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-05-28","current":-3.278382,"twenty":-3.807849,"median":-3.042299,"eighty":-2.11619,"marketCap":40880324},{"date":"2021-06-04","current":-3.471227,"twenty":-3.807849,"median":-3.047644,"eighty":-2.11619,"marketCap":43285047},{"date":"2021-06-11","current":-3.792638,"twenty":-3.808915,"median":-3.051016,"eighty":-2.11619,"marketCap":47292924},{"date":"2021-06-18","current":-3.599792,"twenty":-3.815158,"median":-3.058506,"eighty":-2.11619,"marketCap":44888198},{"date":"2021-06-25","current":-3.696215,"twenty":-3.815158,"median":-3.073824,"eighty":-2.11619,"marketCap":46090561},{"date":"2021-07-02","current":-3.342664,"twenty":-3.814599,"median":-3.085535,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-07-09","current":-3.406946,"twenty":-3.820677,"median":-3.087545,"eighty":-2.11619,"marketCap":42483474},{"date":"2021-07-16","current":-3.149818,"twenty":-3.820677,"median":-3.091406,"eighty":-2.11619,"marketCap":39277173},{"date":"2021-07-23","current":-3.10032,"twenty":-3.820677,"median":-3.101159,"eighty":-2.11619,"marketCap":38659960},{"date":"2021-07-30","current":-3.063037,"twenty":-3.820677,"median":-3.120558,"eighty":-2.11619,"marketCap":38195046},{"date":"2021-08-06","current":-3.2141,"twenty":-3.820677,"median":-3.123123,"eighty":-2.11619,"marketCap":40078748},{"date":"2021-08-13","current":-3.271976,"twenty":-3.820677,"median":-3.12497,"eighty":-2.116451,"marketCap":37922108},{"date":"2021-08-20","current":-3.183049,"twenty":-3.820677,"median":-3.127219,"eighty":-2.128852,"marketCap":36891443},{"date":"2021-08-27","current":-3.529416,"twenty":-3.819297,"median":-3.140414,"eighty":-2.139444,"marketCap":40905829},{"date":"2021-09-03","current":-3.806233,"twenty":-3.819297,"median":-3.149818,"eighty":-2.140169,"marketCap":44114128},{"date":"2021-09-10","current":-4.013846,"twenty":-3.822057,"median":-3.152361,"eighty":-2.145333,"marketCap":46520354},{"date":"2021-09-17","current":-3.737029,"twenty":-3.822117,"median":-3.16435,"eighty":-2.145333,"marketCap":43312052},{"date":"2021-09-24","current":-3.546717,"twenty":-3.822117,"median":-3.180179,"eighty":-2.145333,"marketCap":41106347},{"date":"2021-10-01","current":-3.633222,"twenty":-3.822117,"median":-3.181533,"eighty":-2.145333,"marketCap":42108942},{"date":"2021-10-08","current":-3.59862,"twenty":-3.822117,"median":-3.189617,"eighty":-2.145333,"marketCap":41707904},{"date":"2021-10-15","current":-3.806233,"twenty":-3.822117,"median":-3.197852,"eighty":-2.150499,"marketCap":44114128},{"date":"2021-10-22","current":-3.494814,"twenty":-3.822117,"median":-3.211097,"eighty":-2.154035,"marketCap":40504791},{"date":"2021-10-29","current":-3.494814,"twenty":-3.822117,"median":-3.2141,"eighty":-2.161849,"marketCap":40504791},{"date":"2021-11-05","current":-3.42561,"twenty":-3.822117,"median":-3.220267,"eighty":-2.162699,"marketCap":39702715},{"date":"2021-11-12","current":-2.916544,"twenty":-3.822117,"median":-3.222002,"eighty":-2.170406,"marketCap":39044830},{"date":"2021-11-19","current":-2.741366,"twenty":-3.822117,"median":-3.218265,"eighty":-2.170406,"marketCap":36699653},{"date":"2021-11-26","current":-2.875872,"twenty":-3.822117,"median":-3.216049,"eighty":-2.170406,"marketCap":38500338},{"date":"2021-12-03","current":-2.562024,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":34298742},{"date":"2021-12-10","current":-2.446092,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":32746723},{"date":"2021-12-17","current":-2.394211,"twenty":-3.822117,"median":-3.211931,"eighty":-2.170406,"marketCap":32052174},{"date":"2021-12-23","current":-2.458582,"twenty":-3.822117,"median":-3.203637,"eighty":-2.170406,"marketCap":32913930},{"date":"2021-12-31","current":-2.114631,"twenty":-3.822117,"median":-3.191039,"eighty":-2.169084,"marketCap":28309324},{"date":"2022-01-07","current":-2.217909,"twenty":-3.822097,"median":-3.181959,"eighty":-2.166201,"marketCap":29691947},{"date":"2022-01-14","current":-2.069155,"twenty":-3.813481,"median":-3.181107,"eighty":-2.161849,"marketCap":27700521},{"date":"2022-01-21","current":-2.036489,"twenty":-3.810294,"median":-3.1662,"eighty":-2.161849,"marketCap":27263212},{"date":"2022-01-28","current":-1.97436,"twenty":-3.809605,"median":-3.158329,"eighty":-2.15359,"marketCap":26431467},{"date":"2022-02-04","current":-1.986209,"twenty":-3.809605,"median":-3.149818,"eighty":-2.148285,"marketCap":26590099},{"date":"2022-02-11","current":-2.014712,"twenty":-3.809605,"median":-3.144477,"eighty":-2.14007,"marketCap":26971673},{"date":"2022-02-18","current":-2.17772,"twenty":-3.809605,"median":-3.132783,"eighty":-2.139444,"marketCap":29153928},{"date":"2022-02-25","current":-2.306142,"twenty":-3.809605,"median":-3.129679,"eighty":-2.139444,"marketCap":30873154},{"date":"2022-03-04","current":-2.145054,"twenty":-3.809605,"median":-3.129679,"eighty":-2.138219,"marketCap":28716619},{"date":"2022-03-11","current":-2.312226,"twenty":-3.809605,"median":-3.124184,"eighty":-2.138219,"marketCap":30954613},{"date":"2022-03-18","current":-2.222556,"twenty":-3.806233,"median":-3.11997,"eighty":-2.138219,"marketCap":29754157},{"date":"2022-03-25","current":-2.309344,"twenty":-3.806233,"median":-3.105034,"eighty":-2.138219,"marketCap":30916027},{"date":"2022-04-01","current":-2.532554,"twenty":-3.806233,"median":-3.105034,"eighty":-2.139763,"marketCap":31786020},{"date":"2022-04-08","current":-2.529132,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":31743066},{"date":"2022-04-14","current":-2.481219,"twenty":-3.806233,"median":-3.105034,"eighty":-2.150636,"marketCap":31141708},{"date":"2022-04-22","current":-2.102362,"twenty":-3.806233,"median":-3.105034,"eighty":-2.152006,"marketCap":26386692},{"date":"2022-04-29","current":-1.80975,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":22714119},{"date":"2022-05-06","current":-1.772104,"twenty":-3.806233,"median":-3.105034,"eighty":-2.142794,"marketCap":22241624},{"date":"2022-05-13","current":-1.178605,"twenty":-3.806233,"median":-3.100739,"eighty":-2.140196,"marketCap":17133992},{"date":"2022-05-20","current":-1.543144,"twenty":-3.806233,"median":-3.091406,"eighty":-2.139444,"marketCap":22433476},{"date":"2022-05-27","current":-1.77383,"twenty":-3.806233,"median":-3.089475,"eighty":-2.129342,"marketCap":25787088},{"date":"2022-06-03","current":-1.514419,"twenty":-3.806233,"median":-3.087545,"eighty":-2.119815,"marketCap":22015888},{"date":"2022-06-10","current":-1.776792,"twenty":-3.806233,"median":-3.087545,"eighty":-2.115527,"marketCap":25830138},{"date":"2022-06-17","current":-1.687952,"twenty":-3.806233,"median":-3.087545,"eighty":-2.100887,"marketCap":24538630},{"date":"2022-06-24","current":-1.617473,"twenty":-3.806233,"median":-3.087545,"eighty":-2.092935,"marketCap":23514034},{"date":"2022-07-01","current":-1.719934,"twenty":-3.806233,"median":-3.087545,"eighty":-2.086976,"marketCap":25003573},{"date":"2022-07-08","current":-1.762281,"twenty":-3.806233,"median":-3.087545,"eighty":-2.078536,"marketCap":25619192},{"date":"2022-07-15","current":-2.025543,"twenty":-3.806233,"median":-3.087545,"eighty":-2.0727,"marketCap":29446357},{"date":"2022-07-22","current":-2.259783,"twenty":-3.806233,"median":-3.077014,"eighty":-2.0727,"marketCap":32851632},{"date":"2022-07-29","current":-2.592339,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":37686173},{"date":"2022-08-05","current":-2.679994,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":38960460},{"date":"2022-08-12","current":-2.539174,"twenty":-3.806233,"median":-3.068833,"eighty":-2.0727,"marketCap":38156702},{"date":"2022-08-19","current":-2.380834,"twenty":-3.793261,"median":-3.057725,"eighty":-2.0727,"marketCap":35777295},{"date":"2022-08-26","current":-2.280438,"twenty":-3.77381,"median":-3.037933,"eighty":-2.0727,"marketCap":34268616},{"date":"2022-09-02","current":-2.065302,"twenty":-3.75227,"median":-3.012696,"eighty":-2.072608,"marketCap":31035726},{"date":"2022-09-09","current":-1.986419,"twenty":-3.744873,"median":-2.99389,"eighty":-2.068643,"marketCap":29850333},{"date":"2022-09-16","current":-1.921878,"twenty":-3.736351,"median":-2.972351,"eighty":-2.06071,"marketCap":28880466},{"date":"2022-09-23","current":-1.455464,"twenty":-3.71974,"median":-2.963888,"eighty":-2.050413,"marketCap":21871566},{"date":"2022-09-30","current":-1.252663,"twenty":-3.703324,"median":-2.929273,"eighty":-2.049272,"marketCap":18824029},{"date":"2022-10-07","current":-1.641628,"twenty":-3.69525,"median":-2.907735,"eighty":-2.046565,"marketCap":24669091},{"date":"2022-10-14","current":-1.686663,"twenty":-3.686342,"median":-2.894033,"eighty":-2.042346,"marketCap":25345843},{"date":"2022-10-21","current":-1.804558,"twenty":-3.668494,"median":-2.865205,"eighty":-2.037717,"marketCap":27117466},{"date":"2022-10-28","current":-2.007933,"twenty":-3.667825,"median":-2.841668,"eighty":-2.029514,"marketCap":30173622},{"date":"2022-11-04","current":-1.893481,"twenty":-3.66653,"median":-2.8149,"eighty":-2.026959,"marketCap":28453728},{"date":"2022-11-11","current":-2.05165,"twenty":-3.663597,"median":-2.797124,"eighty":-2.021049,"marketCap":30259092},{"date":"2022-11-18","current":-1.905104,"twenty":-3.648917,"median":-2.778014,"eighty":-2.01711,"marketCap":28097730},{"date":"2022-11-25","current":-1.699939,"twenty":-3.641768,"median":-2.743928,"eighty":-2.014281,"marketCap":25071819},{"date":"2022-12-02","current":-1.64132,"twenty":-3.633222,"median":-2.735277,"eighty":-2.004814,"marketCap":24207273},{"date":"2022-12-09","current":-1.533755,"twenty":-3.633222,"median":-2.711283,"eighty":-1.996265,"marketCap":22620834},{"date":"2022-12-16","current":-1.846485,"twenty":-3.633222,"median":-2.682693,"eighty":-1.984215,"marketCap":27233184},{"date":"2022-12-23","current":-1.891329,"twenty":-3.633222,"median":-2.662821,"eighty":-1.97859,"marketCap":27894562},{"date":"2022-12-30","current":-1.32478,"twenty":-3.633222,"median":-2.64295,"eighty":-1.974296,"marketCap":19538728},{"date":"2023-01-06","current":-1.410357,"twenty":-3.630477,"median":-2.626074,"eighty":-1.970255,"marketCap":20800882},{"date":"2023-01-13","current":-1.377155,"twenty":-3.619207,"median":-2.596781,"eighty":-1.964148,"marketCap":20311194},{"date":"2023-01-20","current":-1.469416,"twenty":-3.619207,"median":-2.584653,"eighty":-1.961265,"marketCap":21671919},{"date":"2023-01-27","current":-1.409182,"twenty":-3.619207,"median":-2.562024,"eighty":-1.955717,"marketCap":20783547},{"date":"2023-02-03","current":-1.351886,"twenty":-3.615611,"median":-2.546439,"eighty":-1.950333,"marketCap":19938511},{"date":"2023-02-10","current":-1.047974,"twenty":-3.615611,"median":-2.539174,"eighty":-1.93629,"marketCap":15456214},{"date":"2023-02-17","current":-0.812914,"twenty":-3.615611,"median":-2.519549,"eighty":-1.920521,"marketCap":11989399},{"date":"2023-02-24","current":-0.744355,"twenty":-3.615611,"median":-2.50894,"eighty":-1.916691,"marketCap":10978245},{"date":"2023-03-03","current":-0.579814,"twenty":-3.615611,"median":-2.50315,"eighty":-1.905104,"marketCap":8551475},{"date":"2023-03-10","current":-0.628784,"twenty":-3.615611,"median":-2.498294,"eighty":-1.893481,"marketCap":9273728},{"date":"2023-03-17","current":-0.45249,"twenty":-3.615611,"median":-2.494874,"eighty":-1.873469,"marketCap":6673617},{"date":"2023-03-24","current":-0.360425,"twenty":-3.615611,"median":-2.490459,"eighty":-1.864593,"marketCap":5315782},{"date":"2023-03-31","current":-0.385889,"twenty":-3.614644,"median":-2.487664,"eighty":-1.852184,"marketCap":5691353},{"date":"2023-04-06","current":-0.368498,"twenty":-3.614644,"median":-2.487664,"eighty":-1.838884,"marketCap":5084661},{"date":"2023-04-14","current":-0.343373,"twenty":-3.615611,"median":-2.488267,"eighty":-1.81823,"marketCap":4737979},{"date":"2023-04-21","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.806924,"marketCap":4298921},{"date":"2023-04-28","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.796476,"marketCap":4298921},{"date":"2023-05-05","current":-0.486536,"twenty":-3.615611,"median":-2.488267,"eighty":-1.780665,"marketCap":6713384},{"date":"2023-05-12","current":-0.530952,"twenty":-3.615611,"median":-2.488267,"eighty":-1.774785,"marketCap":7326252},{"date":"2023-05-19","current":-0.450777,"twenty":-3.615611,"median":-2.488267,"eighty":-1.773356,"marketCap":4731101},{"date":"2023-05-26","current":-0.548639,"twenty":-3.615611,"median":-2.488267,"eighty":-1.762981,"marketCap":5758198},{"date":"2023-06-02","current":-0.556758,"twenty":-3.615611,"median":-2.488267,"eighty":-1.761231,"marketCap":5843414},{"date":"2023-06-09","current":-0.568435,"twenty":-3.615611,"median":-2.488267,"eighty":-1.758431,"marketCap":5965964},{"date":"2023-06-16","current":-0.553201,"twenty":-3.615611,"median":-2.488267,"eighty":-1.753075,"marketCap":5806081},{"date":"2023-06-23","current":-0.549104,"twenty":-3.616579,"median":-2.489363,"eighty":-1.755221,"marketCap":5763076},{"date":"2023-06-30","current":-0.549025,"twenty":-3.617546,"median":-2.490459,"eighty":-1.751843,"marketCap":5762256},{"date":"2023-07-07","current":-0.561243,"twenty":-3.617546,"median":-2.490459,"eighty":-1.719975,"marketCap":5890486},{"date":"2023-07-14","current":-0.534333,"twenty":-3.617546,"median":-2.490459,"eighty":-1.701031,"marketCap":5608055},{"date":"2023-07-21","current":-0.517398,"twenty":-3.617546,"median":-2.488267,"eighty":-1.696019,"marketCap":5430317},{"date":"2023-07-28","current":-0.487163,"twenty":-3.617546,"median":-2.48706,"eighty":-1.691433,"marketCap":5112988},{"date":"2023-08-04","current":-0.458552,"twenty":-3.617546,"median":-2.471478,"eighty":-1.68556,"marketCap":4812701},{"date":"2023-08-11","current":-0.492307,"twenty":-3.605533,"median":-2.464449,"eighty":-1.673383,"marketCap":5166973},{"date":"2023-08-18","current":-0.451047,"twenty":-3.604385,"median":-2.451581,"eighty":-1.658517,"marketCap":4733931},{"date":"2023-08-25","current":-0.474846,"twenty":-3.599792,"median":-2.429294,"eighty":-1.650503,"marketCap":4615829},{"date":"2023-09-01","current":-0.455119,"twenty":-3.59581,"median":-2.407007,"eighty":-1.641321,"marketCap":4424070},{"date":"2023-09-08","current":-0.515598,"twenty":-3.574766,"median":-2.401897,"eighty":-1.635487,"marketCap":5011970},{"date":"2023-09-15","current":-0.457243,"twenty":-3.566924,"median":-2.38362,"eighty":-1.627894,"marketCap":4444715},{"date":"2023-09-22","current":-0.50771,"twenty":-3.560315,"median":-2.374811,"eighty":-1.617598,"marketCap":4935296},{"date":"2023-09-29","current":-0.546143,"twenty":-3.551056,"median":-2.338167,"eighty":-1.605284,"marketCap":5308884},{"date":"2023-10-06","current":-0.576484,"twenty":-3.535509,"median":-2.330801,"eighty":-1.598066,"marketCap":5603822},{"date":"2023-10-13","current":-0.56637,"twenty":-3.529416,"median":-2.317858,"eighty":-1.582702,"marketCap":5505509},{"date":"2023-10-20","current":-0.529961,"twenty":-3.529416,"median":-2.309344,"eighty":-1.582674,"marketCap":5151583},{"date":"2023-10-27","current":-0.515296,"twenty":-3.529416,"median":-2.303676,"eighty":-1.573299,"marketCap":5009030},{"date":"2023-11-03","current":-0.488595,"twenty":-3.529416,"median":-2.295319,"eighty":-1.555321,"marketCap":4749485},{"date":"2023-11-10","current":-0.420732,"twenty":-3.529416,"median":-2.279706,"eighty":-1.52544,"marketCap":4089807},{"date":"2023-11-17","current":-0.49227,"twenty":-3.529416,"median":-2.266533,"eighty":-1.497359,"marketCap":3974781},{"date":"2023-11-24","current":-0.519915,"twenty":-3.529416,"median":-2.255719,"eighty":-1.484111,"marketCap":4197997},{"date":"2023-12-01","current":-1.259878,"twenty":-3.529416,"median":-2.246954,"eighty":-1.471408,"marketCap":10172748},{"date":"2023-12-08","current":-0.944716,"twenty":-3.529416,"median":-2.243626,"eighty":-1.458806,"marketCap":7628004},{"date":"2023-12-15","current":-0.760271,"twenty":-3.529416,"median":-2.242091,"eighty":-1.44978,"marketCap":6138727},{"date":"2023-12-22","current":-0.781479,"twenty":-3.529416,"median":-2.242091,"eighty":-1.42203,"marketCap":6309968},{"date":"2023-12-29","current":-0.878907,"twenty":-3.529416,"median":-2.242858,"eighty":-1.409887,"marketCap":7096639},{"date":"2024-01-05","current":-1.166178,"twenty":-3.529416,"median":-2.243626,"eighty":-1.402478,"marketCap":9416175},{"date":"2024-01-12","current":-1.113479,"twenty":-3.529416,"median":-2.241771,"eighty":-1.377273,"marketCap":8990667},{"date":"2024-01-19","current":-0.798188,"twenty":-3.529416,"median":-2.240902,"eighty":-1.367144,"marketCap":6444885},{"date":"2024-01-26","current":-0.76477,"twenty":-3.529416,"median":-2.232464,"eighty":-1.350711,"marketCap":6175051},{"date":"2024-02-02","current":-0.861041,"twenty":-3.529416,"median":-2.232464,"eighty":-1.323591,"marketCap":6952381},{"date":"2024-02-09","current":-0.832892,"twenty":-3.529416,"median":-2.232464,"eighty":-1.284479,"marketCap":6725098},{"date":"2024-02-16","current":-0.935719,"twenty":-3.529416,"median":-2.232464,"eighty":-1.19338,"marketCap":7555357},{"date":"2024-02-23","current":-0.96014,"twenty":-3.529416,"median":-2.232464,"eighty":-1.170061,"marketCap":7752543},{"date":"2024-03-01","current":-0.937004,"twenty":-3.529416,"median":-2.232314,"eighty":-1.094071,"marketCap":7565735},{"date":"2024-03-08","current":-1.015409,"twenty":-3.529416,"median":-2.232314,"eighty":-1.04266,"marketCap":8198808},{"date":"2024-03-15","current":-0.818497,"twenty":-3.529416,"median":-2.232314,"eighty":-0.985743,"marketCap":6608861},{"date":"2024-03-22","current":-1.096879,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6735639},{"date":"2024-03-28","current":-1.040493,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6389385},{"date":"2024-04-05","current":-0.805692,"twenty":-3.529416,"median":-2.232163,"eighty":-0.951971,"marketCap":4947537},{"date":"2024-04-12","current":-0.666183,"twenty":-3.529416,"median":-2.232163,"eighty":-0.937467,"marketCap":4090848},{"date":"2024-04-19","current":-0.746049,"twenty":-3.529416,"median":-2.232163,"eighty":-0.925458,"marketCap":4581287},{"date":"2024-04-26","current":-0.990316,"twenty":-3.529416,"median":-2.231918,"eighty":-0.92158,"marketCap":6081264},{"date":"2024-05-03","current":-0.938133,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5760823},{"date":"2024-05-10","current":-0.941612,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5782185},{"date":"2024-05-17","current":-0.792348,"twenty":-3.529416,"median":-2.231918,"eighty":-0.90316,"marketCap":5554316},{"date":"2024-05-24","current":-0.729366,"twenty":-3.529416,"median":-2.231918,"eighty":-0.885025,"marketCap":5112819},{"date":"2024-05-31","current":-0.711081,"twenty":-3.529416,"median":-2.231918,"eighty":-0.868111,"marketCap":4984642},{"date":"2024-06-07","current":-0.584609,"twenty":-3.529416,"median":-2.231918,"eighty":-0.841478,"marketCap":4098079},{"date":"2024-06-14","current":-0.584609,"twenty":-3.529416,"median":-2.232163,"eighty":-0.825714,"marketCap":4098079},{"date":"2024-06-21","current":-0.5184,"twenty":-3.529416,"median":-2.232314,"eighty":-0.813414,"marketCap":3633959},{"date":"2024-06-28","current":-0.373304,"twenty":-3.529416,"median":-2.233626,"eighty":-0.808757,"marketCap":2616845},{"date":"2024-07-05","current":-0.318365,"twenty":-3.529416,"median":-2.233626,"eighty":-0.804561,"marketCap":2231725},{"date":"2024-07-12","current":-1.077653,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7554290},{"date":"2024-07-15","current":-1.046662,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7337043},{"date":"2024-08-02","current":-0.618418,"twenty":-3.535509,"median":-2.215749,"eighty":-0.797123,"marketCap":4335076},{"date":"2024-08-09","current":-0.442331,"twenty":-3.535509,"median":-2.205592,"eighty":-0.792348,"marketCap":3100715},{"date":"2024-08-16","current":-1.081532,"twenty":-3.535509,"median":-2.189844,"eighty":-0.792348,"marketCap":7616606},{"date":"2024-08-23","current":-1.372962,"twenty":-3.535509,"median":-2.17772,"eighty":-0.792348,"marketCap":9668985},{"date":"2024-08-30","current":-1.058865,"twenty":-3.535509,"median":-2.174327,"eighty":-0.792348,"marketCap":7456976},{"date":"2024-09-06","current":-1.343819,"twenty":-3.535509,"median":-2.166303,"eighty":-0.792348,"marketCap":9463747},{"date":"2024-09-13","current":-1.110675,"twenty":-3.535509,"median":-2.161246,"eighty":-0.792348,"marketCap":7821844},{"date":"2024-09-20","current":-1.240199,"twenty":-3.535509,"median":-2.156951,"eighty":-0.792348,"marketCap":8734012},{"date":"2024-09-27","current":-1.246676,"twenty":-3.535509,"median":-2.145374,"eighty":-0.792348,"marketCap":8779620},{"date":"2024-10-04","current":-1.279057,"twenty":-3.535509,"median":-2.13956,"eighty":-0.792348,"marketCap":9007662},{"date":"2024-10-11","current":-1.292009,"twenty":-3.535509,"median":-2.13101,"eighty":-0.792348,"marketCap":9098879},{"date":"2024-10-18","current":-1.175437,"twenty":-3.535509,"median":-2.12822,"eighty":-0.792348,"marketCap":8277928},{"date":"2024-10-25","current":-1.20458,"twenty":-3.535509,"median":-2.123577,"eighty":-0.792348,"marketCap":8483166},{"date":"2024-10-31","current":-1.207818,"twenty":-3.535509,"median":-2.107658,"eighty":-0.792348,"marketCap":8505970},{"date":"2024-11-08","current":-1.123627,"twenty":-3.535509,"median":-2.074279,"eighty":-0.792348,"marketCap":7913060},{"date":"2024-11-15","current":-1.300862,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":9234956},{"date":"2024-11-22","current":-1.187744,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":8431916},{"date":"2024-11-29","current":-1.184209,"twenty":-3.535509,"median":-2.049939,"eighty":-0.792348,"marketCap":8406821},{"date":"2024-12-06","current":-1.131184,"twenty":-3.535509,"median":-2.033927,"eighty":-0.792348,"marketCap":8030396},{"date":"2024-12-13","current":-1.170069,"twenty":-3.535509,"median":-2.017112,"eighty":-0.792348,"marketCap":8306441},{"date":"2024-12-20","current":-1.088765,"twenty":-3.535509,"median":-2.001581,"eighty":-0.792348,"marketCap":7729256},{"date":"2024-12-27","current":-1.021601,"twenty":-3.535509,"median":-1.986209,"eighty":-0.792348,"marketCap":7252452},{"date":"2025-01-03","current":-1.039276,"twenty":-3.535509,"median":-1.976601,"eighty":-0.792348,"marketCap":7377927},{"date":"2025-01-10","current":-1.155929,"twenty":-3.529416,"median":-1.97197,"eighty":-0.792348,"marketCap":8206061},{"date":"2025-01-17","current":-0.802434,"twenty":-3.523734,"median":-1.964077,"eighty":-0.792348,"marketCap":5696562},{"date":"2025-01-24","current":-0.887273,"twenty":-3.508918,"median":-1.953718,"eighty":-0.792348,"marketCap":6298842},{"date":"2025-01-31","current":-0.816574,"twenty":-3.487384,"median":-1.94499,"eighty":-0.792348,"marketCap":5796942},{"date":"2025-02-07","current":-0.830713,"twenty":-3.464081,"median":-1.928314,"eighty":-0.792348,"marketCap":5897322},{"date":"2025-02-14","current":-0.869598,"twenty":-3.460004,"median":-1.914564,"eighty":-0.792348,"marketCap":6173367},{"date":"2025-02-21","current":-0.862528,"twenty":-3.449367,"median":-1.905104,"eighty":-0.792348,"marketCap":6123177},{"date":"2025-02-28","current":-0.795364,"twenty":-3.435067,"median":-1.886817,"eighty":-0.792348,"marketCap":5646372},{"date":"2025-03-07","current":-0.823644,"twenty":-3.423562,"median":-1.846485,"eighty":-0.790373,"marketCap":5847132},{"date":"2025-03-14","current":-0.813039,"twenty":-3.41639,"median":-1.80975,"eighty":-0.790373,"marketCap":5771847},{"date":"2025-03-21","current":-0.841318,"twenty":-3.407348,"median":-1.782714,"eighty":-0.790373,"marketCap":5972607},{"date":"2025-03-28","current":-0.866528,"twenty":-3.405471,"median":-1.77383,"eighty":-0.790373,"marketCap":7163218},{"date":"2025-04-04","current":-0.794114,"twenty":-3.378355,"median":-1.754307,"eighty":-0.790373,"marketCap":6564600},{"date":"2025-04-11","current":-0.72147,"twenty":-3.370724,"median":-1.718749,"eighty":-0.782944,"marketCap":5964089},{"date":"2025-04-17","current":-0.786365,"twenty":-3.368231,"median":-1.700232,"eighty":-0.779049,"marketCap":6500542},{"date":"2025-04-25","current":-0.822629,"twenty":-3.349519,"median":-1.687952,"eighty":-0.778595,"marketCap":6800324},{"date":"2025-05-02","current":-0.732922,"twenty":-3.335701,"median":-1.677345,"eighty":-0.767341,"marketCap":6058757},{"date":"2025-05-09","current":-0.752009,"twenty":-3.318337,"median":-1.658339,"eighty":-0.75921,"marketCap":6216537},{"date":"2025-05-16","current":-0.625327,"twenty":-3.306695,"median":-1.64132,"eighty":-0.752009,"marketCap":5995645},{"date":"2025-05-23","current":-0.623044,"twenty":-3.300954,"median":-1.631589,"eighty":-0.744363,"marketCap":5973753},{"date":"2025-05-30","current":-0.653685,"twenty":-3.291097,"median":-1.613804,"eighty":-0.737916,"marketCap":6267544},{"date":"2025-06-06","current":-0.626449,"twenty":-3.282404,"median":-1.587127,"eighty":-0.732937,"marketCap":6006396},{"date":"2025-06-13","current":-0.626449,"twenty":-3.276897,"median":-1.572151,"eighty":-0.718851,"marketCap":6006396},{"date":"2025-06-20","current":-0.607723,"twenty":-3.27413,"median":-1.559154,"eighty":-0.711081,"marketCap":5826857},{"date":"2025-06-27","current":-0.466432,"twenty":-3.268842,"median":-1.519397,"eighty":-0.698758,"marketCap":4472154},{"date":"2025-07-03","current":-0.408553,"twenty":-3.257603,"median":-1.473383,"eighty":-0.664356,"marketCap":3917215},{"date":"2025-07-11","current":-0.432386,"twenty":-3.236874,"median":-1.452959,"eighty":-0.65419,"marketCap":4145719},{"date":"2025-07-18","current":-0.463027,"twenty":-3.217218,"median":-1.430621,"eighty":-0.643472,"marketCap":4439510},{"date":"2025-07-25","current":-0.473241,"twenty":-3.2141,"median":-1.408221,"eighty":-0.637343,"marketCap":4537440},{"date":"2025-08-01","current":-0.997551,"twenty":-3.188721,"median":-1.381754,"eighty":-0.627362,"marketCap":9564533},{"date":"2025-08-08","current":-1.120117,"twenty":-3.181107,"median":-1.370141,"eighty":-0.627362,"marketCap":10739698},{"date":"2025-08-15","current":-1.000956,"twenty":-3.164793,"median":-1.351886,"eighty":-0.627362,"marketCap":9597177},{"date":"2025-08-22","current":-1.389916,"twenty":-3.149818,"median":-1.351739,"eighty":-0.627362,"marketCap":14399515},{"date":"2025-08-29","current":-1.265816,"twenty":-3.133169,"median":-1.335619,"eighty":-0.627362,"marketCap":13113844},{"date":"2025-09-05","current":-1.257543,"twenty":-3.117677,"median":-1.322798,"eighty":-0.627006,"marketCap":13028132},{"date":"2025-09-12","current":-1.14999,"twenty":-3.103112,"median":-1.30595,"eighty":-0.627362,"marketCap":11913884},{"date":"2025-09-19","current":-1.141717,"twenty":-3.087143,"median":-1.297273,"eighty":-0.627362,"marketCap":11828173},{"date":"2025-09-26","current":-0.670138,"twenty":-3.067674,"median":-1.286016,"eighty":-0.627362,"marketCap":6942623},{"date":"2025-10-03","current":-0.529492,"twenty":-3.01938,"median":-1.275424,"eighty":-0.623501,"marketCap":5485529},{"date":"2025-10-10","current":-1.442653,"twenty":-2.995922,"median":-1.267432,"eighty":-0.616672,"marketCap":14945873},{"date":"2025-10-17","current":-1.249225,"twenty":-2.91443,"median":-1.264341,"eighty":-0.616672,"marketCap":12941957},{"date":"2025-10-24","current":-1.289522,"twenty":-2.875231,"median":-1.264341,"eighty":-0.616672,"marketCap":13359440},{"date":"2025-10-31","current":-1.216987,"twenty":-2.813038,"median":-1.258586,"eighty":-0.616672,"marketCap":12607971},{"date":"2025-11-07","current":-1.031618,"twenty":-2.781244,"median":-1.253152,"eighty":-0.616672,"marketCap":10687552},{"date":"2025-11-14","current":-1.245919,"twenty":-2.740725,"median":-1.250644,"eighty":-0.616672,"marketCap":13918859},{"date":"2025-11-21","current":-1.146607,"twenty":-2.677684,"median":-1.246297,"eighty":-0.616672,"marketCap":12809385},{"date":"2025-11-28","current":-1.435516,"twenty":-2.656351,"median":-1.246297,"eighty":-0.616672,"marketCap":16036946},{"date":"2025-12-05","current":-1.471629,"twenty":-2.625475,"median":-1.246297,"eighty":-0.616672,"marketCap":16440391},{"date":"2025-12-12","current":-1.471629,"twenty":-2.589141,"median":-1.246297,"eighty":-0.616672,"marketCap":16440391},{"date":"2025-12-19","current":-1.110493,"twenty":-2.546865,"median":-1.242649,"eighty":-0.616672,"marketCap":12405939},{"date":"2025-12-26","current":-1.30009,"twenty":-2.53187,"median":-1.240895,"eighty":-0.616672,"marketCap":14524027},{"date":"2026-01-02","current":-1.209806,"twenty":-2.515486,"median":-1.23858,"eighty":-0.616672,"marketCap":13515414},{"date":"2026-01-09","current":-1.30009,"twenty":-2.498557,"median":-1.23858,"eighty":-0.616672,"marketCap":14524027},{"date":"2026-01-16","current":-1.209806,"twenty":-2.489022,"median":-1.236891,"eighty":-0.616672,"marketCap":13515414},{"date":"2026-01-23","current":-1.282033,"twenty":-2.465907,"median":-1.236891,"eighty":-0.616672,"marketCap":14322304},{"date":"2026-01-30","current":-1.182721,"twenty":-2.437573,"median":-1.23371,"eighty":-0.616672,"marketCap":13212830},{"date":"2026-02-06","current":-0.938954,"twenty":-2.392653,"median":-1.223977,"eighty":-0.616672,"marketCap":10489575}],"updateTime":1770681993774},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNGX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605837242","title":"BRIEF-Soligenix Inc Enters Sales Agreement With Rodman","url":"https://stock-news.laohu8.com/highlight/detail?id=2605837242","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605837242?lang=en_us&edition=fundamental","pubTime":"2026-01-24 05:35","pubTimestamp":1769204106,"startTime":"0","endTime":"0","summary":"BRIEF-Soligenix Enters Sales Agreement With Rodman Jan 23  - Soligenix Inc SNGX.O:SOLIGENIX INC - ENTERS SALES AGREEMENT WITH RODMAN - SEC FILINGSOLIGENIX INC - TO OFFER SHARES UP TO $3.45 MILLION - SEC FILINGSource text: [ID:n0001104659-26-006233]Further company coverage: SNGX.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO1E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2601398634","title":"Soligenix Showcases Rare Disease Pipeline and Market Potential in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601398634","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601398634?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:36","pubTimestamp":1767882979,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has released a corporate presentation outlining its progress in developing treatments for rare diseases and public health threats. The company highlights its late-stage pipeline, which includes HyBryte  for cutaneous T-cell lymphoma with positive Phase 3 results and ongoing confirmatory studies. Other clinical-stage assets include SGX302 for psoriasis and SGX945 for Behet's disease, both with orphan designations. The presentation details significant funding from federal sources, including NIH contracts and grants, and estimates a total addressable global market potential of approximately $2 billion in annual sales across its portfolio. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8LywFp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592903090","title":"Soligenix Reports Positive Phase 2 Results for SGX945 in Behçet's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903090","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592903090?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061055,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has announced the publication of positive results from its Phase 2a proof of concept study evaluating SGX945  for the treatment of Behet's Disease in the journal Rheumatology . The study focused on patients with aphthous ulcers associated with Behet's Disease. Results demonstrated that SGX945 treatment led to improvements in oral pain, reduced duration and number of oral ulcers, and was well-tolerated with no treatment-related adverse events reported. The improvements were sustained during a follow-up period after treatment had ended. Soligenix plans to pursue a reformulation of SGX945 to enable home-based subcutaneous administration and intends to engage regulatory authorities for the design of a follow-on clinical study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL9FbjQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592890306","title":"Soligenix Inc - Sgx945 Well-Tolerated With No Treatment-Related Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2592890306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592890306?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA6BPNKW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592037439","title":"Positive Clinical Results From Phase 2 Trial of Sgx945 for the Treatment of BehÇEt's Disease Published in Rheumatology (Oxford)","url":"https://stock-news.laohu8.com/highlight/detail?id=2592037439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592037439?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA6BPNKW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592296990","title":"Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302","url":"https://stock-news.laohu8.com/highlight/detail?id=2592296990","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592296990?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:10","pubTimestamp":1765977028,"startTime":"0","endTime":"0","summary":"Dec 17 (Reuters) - Soligenix Inc ::*SOLIGENIX ANNOUNCES TOP-LINE RESULTS OF THE PHASE 2A STUDY OF SGX302 (SYNTHETIC HYPERICIN) IN PATIENTS WITH MILD-TO-MODERATE PSORIASIS*SOLIGENIX INC - OPTIMIZED GEL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nRSD4Mqw9S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592997512","title":"Soligenix Reports Positive Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997512","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997512?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974655,"startTime":"0","endTime":"0","summary":"Soligenix Inc. announced extended results from its ongoing Phase 2a clinical trial of SGX302  for the treatment of mild-to-moderate psoriasis. The extension, involving a third cohort of patients, assessed an improved topical gel formulation of the drug. The gel was designed to enhance ease of application to larger skin areas. According to the company, SGX302 gel therapy was well tolerated with no drug-related adverse events observed. Improvements were reported in multiple clinical indices, including the Investigator Global Assessment and Psoriasis Activity and Severity Index. The results from this extension have already been presented by Soligenix. The company plans to continue evaluating SGX302 in psoriasis, while it also advances a confirmatory Phase 3 trial for HyBryte in early-stage cutaneous T-cell lymphoma, with topline results for that study expected in the second half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL1qsRq7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2592997572","title":"Soligenix Inc - Study Confirms Sgx302 Improves Psoriasis Lesions","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997572?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4X9TPW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2592997520","title":"Soligenix Inc - Optimized Gel Formulation Shows Success in Third Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997520?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4X9TPW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592699782","title":"Soligenix Announces Top-Line Results of the Phase 2a Study of Sgx302 (Synthetic Hypericin) in Patients With Mild-to-Moderate Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2592699782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592699782?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4X9TPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592571997","title":"Soligenix Inc - Sgx302 Gel Therapy Well Tolerated With No Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2592571997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592571997?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4X9TPW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2589890136","title":"Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad","url":"https://stock-news.laohu8.com/highlight/detail?id=2589890136","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589890136?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:30","pubTimestamp":1764941400,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  05, 2025  (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands withinthe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200703/0/en/Soligenix-Inc-NASDAQ-SNGX-Advancing-Rare-Disease-Therapies-Positioned-at-Pivotal-Crossroad.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","TSYW.SI","BK4604","03160","BK4585","SNGX","BK4022","BK4232","BK4099","QID","BK4555","MNQmain","PSQ",".IXIC","NVIW.SI","SQQQ","USAW.SI","TQQQ","USJW.SI","BK4588","BK4139","TM","NQmain","QLD"],"gpt_icon":1},{"id":"2588413320","title":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2588413320","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588413320?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:30","pubTimestamp":1764768600,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands withinthe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198880/0/en/Soligenix-Inc-NASDAQ-SNGX-Innovative-Platform-Provides-Novel-Treatment-for-Underserved-CTCL-Space.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","QLD","TQQQ","TM","NQmain","BK4588","BK4232","BK4099","SQQQ","BK4555","NVIW.SI","03160","MNQmain","R","USJW.SI","BK4585","TSYW.SI","BK4139","USAW.SI","BK4022",".IXIC","QID","BK4604","SNGX"],"gpt_icon":1},{"id":"2586491196","title":"Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586491196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586491196?lang=en_us&edition=fundamental","pubTime":"2025-11-25 01:52","pubTimestamp":1764006762,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behet's Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the fu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5vYRK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2584946056","title":"Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte","url":"https://stock-news.laohu8.com/highlight/detail?id=2584946056","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584946056?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:35","pubTimestamp":1763555743,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced that it has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80 patient confirm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenix-completes-enrollment-of-patients-for-phase-3-study-evaluating-hybryte-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenix-completes-enrollment-of-patients-for-phase-3-study-evaluating-hybryte-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2584946131","title":"Soligenix Reaches Interim Enrollment Milestone in Phase 3 HyBryte Trial for CTCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2584946131","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584946131?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:30","pubTimestamp":1763555441,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has announced the completion of patient enrollment for the planned interim analysis in its confirmatory Phase 3 clinical trial of HyBryte  for the treatment of cutaneous T-cell lymphoma . The trial, known as FLASH2, has enrolled 50 out of a total 80 patients, reaching a key milestone for the interim analysis, which is scheduled to occur in the second quarter of 2026. The company reports that the overall blinded study response rate to date is 48%, exceeding the initial estimate of 25%. Topline results from the study are expected in the second half of 2026. Results from this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL6LSLPH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2584946911","title":"Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™ for the Treatment of Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2584946911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584946911?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:30","pubTimestamp":1763555416,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV10H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2584965976","title":"Soligenix Regains Nasdaq Compliance After Equity Shortfall","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965976?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:06","pubTimestamp":1763499962,"startTime":"0","endTime":"0","summary":"Soligenix Inc. announced that it has resolved a recent regulatory issue concerning its listing on the Nasdaq Capital Market. The company previously received notice from Nasdaq that it was not in compliance with the minimum stockholders' equity requirement of $2.5 million. However, Soligenix reported stockholders' equity of $7.6 million in its latest quarterly report, surpassing the required threshold. Nasdaq has confirmed that Soligenix has regained compliance and the matter is now closed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL9ZSMJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2581000480","title":"Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000480","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000480?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:40","pubTimestamp":1762519253,"startTime":"0","endTime":"0","summary":"Biopharma firm Soligenix's Q3 net loss widens on increased R&D spendsOverviewSoligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expensesCompany reports no revenue for Q3 2025, sa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ0IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2581554000","title":"Soligenix Reports Net Loss of $2.5 Million With No Revenue in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581554000","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581554000?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:31","pubTimestamp":1762518676,"startTime":"0","endTime":"0","summary":"Soligenix Inc. reported no revenue for the quarters ended September 30, 2025 and 2024. The company posted a net loss of $2.5 million, or $0.58 per share, for the third quarter of 2025, compared to a net loss of $1.7 million, or $0.78 per share, for the same period in 2024. The increase in net loss was attributed to higher operating expenses related to clinical trials, decreased interest income, and the absence of a CARES Act employee retention credit received in the previous year. As of September 30, 2025, Soligenix held approximately $10.5 million in cash, which is expected to fund operations through 2026. Recent business developments include updates to the U.S. Medical Advisory Board for the Phase 3 development of HyBryte for CTCL and the FDA granting orphan drug designation to dusquetide for the treatment of Behet's Disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL23kVWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}]}}